Product Information

TROKENDI XR 200 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $41.4375 per EA under NDC 17772010401. Its NADAC has been published 549 times since Dec 31, 2014.

FDA first approved this application on Aug 16, 2013. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TROKENDI XR 200 MG CAPSULE

topiramate
$41.4375per EA

Strength

200 mg/1

NDC

17772010401

Classification

Brand

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

6/18/2025

Active Ingredients

TOPIRAMATE

Approval Type

New Drug (NDA)

FDA Application

NDA201635

FDA Approved

8/16/2013

TE Code

AB1

On Market Since

8/16/2013

Pharmacological Classes

Cytochrome P450 2C19 Inhibitors
Cytochrome P450 3A4 Inducers
Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for TROKENDI XR 200 MG CAPSULE has been published 549 times since Dec 31, 2014, and over the history we have for it it has risen 111.3%. The table below summarizes its recorded NADAC range and movement.

Current price$41.4375 per EA
All-time high$41.5897 (Sep 11, 2024)
All-time low$19.6070 (Dec 31, 2014)
Median price$34.9042
Average price$33.4017
Largest weekly change+9.0% (Feb 3, 2016)
Weeks tracked549
Tracking sinceDec 31, 2014

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

-0.3%

5Y

+12.1%

All

+111.3%

Last surveyed Jul 2, 2025 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 77% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of TROKENDI XR 200 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for TROKENDI XR 200 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $41.4375 per EA (NDC 17772010401), effective Jul 2, 2025.

How has the price of TROKENDI XR 200 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for TROKENDI XR 200 MG CAPSULE has risen 111.3%. It has been tracked across 549 weekly CMS publications since Dec 31, 2014.

What are the highest and lowest recorded NADAC prices for TROKENDI XR 200 MG CAPSULE?

Since Dec 31, 2014, the NADAC for TROKENDI XR 200 MG CAPSULE has ranged from a low of $19.6070 (Dec 31, 2014) to a high of $41.5897 (Sep 11, 2024), with a median of $34.9042 per EA.

Are there cheaper alternatives to TROKENDI XR 200 MG CAPSULE?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 200 MG SPRINK CAP, is $9.6713 per EA — about 77% below TROKENDI XR 200 MG CAPSULE.

Who manufactures TROKENDI XR 200 MG CAPSULE?

TROKENDI XR 200 MG CAPSULE (NDC 17772010401) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.